ALDX
Aldeyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.66
−3.58%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +55.9%
- EBIT
- +54.9%
- EPS
- +54.4%
- Free cash flow
- +46.3%
- Operating cash flow
- +46.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +17.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +41.0%
- EBIT
- +41.3%
- Net income
- +39.4%
- EPS
- +40.4%
- Free cash flow
- +22.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026